Novel Selective Phosphodiesterase Type 1 Inhibitors; a Comprehensive in vitro, ex vivo and in vivo Assessment of Cardiovascular Effects

被引：0
|
作者：
Laursen, M. [1 ]
Beck, L. [2 ]
Bangshaab, M. [2 ]
Christoffersen, C. T. [1 ]
Bundgaard, C. [1 ]
Mogensen, S. [2 ]
Hedegaard, E. R. [2 ]
Mow, T. [1 ]
Grunnet, M. [2 ,3 ]
Simonsen, U. [2 ]
机构：
[1] Lundbeck AS, Copenhagen, Denmark
[2] Aarhus Univ, Dept Biomed Pulm & Cardiovasc Pharmacol, DK-8000 Aarhus C, Denmark
[3] Univ Copenhagen, Dept Drug Design & Pharmacol, DK-1168 Copenhagen, Denmark
来源：
JOURNAL OF VASCULAR RESEARCH | 2016年 / 53卷
关键词：
D O I：
暂无
中图分类号：
Q4 [生理学];
学科分类号：
071003 ;
摘要：
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [31] In vivo, ex vivo and in vitro assessment of buccal permeation of drugs from delivery systems
    Pinto, Soraia
    Pintado, Manuela E.
    Sarmento, Bruno
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (01) : 33 - 48
  • [32] Toxicological Assessment of Inhaled Nanoparticles: Role of in Vivo, ex Vivo, in Vitro, and in Silico Studies
    Froehlich, Eleonore
    Salar-Behzadi, Sharareh
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (03) : 4795 - 4822
  • [33] Enhancement of the Clastogenic Effects of Topotecan In Vivo by Tyrosyl-DNA Phosphodiesterase 1 Inhibitors
    Zhanataev, A. K.
    Kulakova, A. V.
    Luzina, O. A.
    Khomenko, T. M.
    Volcho, K. P.
    Salakhutdinov, N. F.
    Durnev, A. D.
    [J]. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2024, 177 (01) : 30 - 34
  • [34] NOVEL COUMARIN DERIVATIVES AS SELECTIVE MAO-B INHIBITORS: IN VITRO AND IN VIVO ASSAYS
    Rodriguez-Enriquez, F.
    Quezada, E.
    Matos, M. J.
    Costas-Lago, M. C.
    Mayan, L.
    Laguna, R.
    Uriarte, E.
    Vina, D.
    Fontenla, J. A.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 36 - 36
  • [35] In vivo and in vitro acute cardiovascular effects of bimoclomol
    Jednákovits, A
    Ferdinándy, P
    Jaszlits, L
    Bányász, T
    Magyar, J
    Szigligeti, P
    Körtvély, A
    Szentmiklósi, JA
    Nánási, PP
    [J]. GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 2000, 34 (05): : 363 - 369
  • [36] In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline
    Tanaka, S. Ken
    Villano, Stephen
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) : 5247 - 5253
  • [37] In vitro and in vivo effects of inhibitors on actin and myosin
    Richter, Sabine
    Martin, Rene
    Gutzeit, Herwig O.
    Knoelker, Hans-Joachim
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 30
  • [38] Manganese ferrite-based nanoparticles induce ex vivo, but not in vivo, cardiovascular effects
    Nunes, Allancer D. C.
    Ramalho, Laylla S.
    Souza, Alvaro P. S.
    Mendes, Elizabeth P.
    Colugnati, Diego B.
    Zufelato, Nicholas
    Sousa, Marcelo H.
    Bakuzis, Andris F.
    Castro, Carlos H.
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2014, 9 : 3299 - 3312
  • [39] Repurposing sarecycline for osteoinductive therapies: an in vitro and ex vivo assessment
    Martin, Victor
    Grenho, Liliana
    Fernandes, Maria H.
    Gomes, Pedro S.
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2023, 41 (04) : 431 - 442
  • [40] In vitro-ex vivo model systems for nanosafety assessment
    Wick, Peter
    Chortarea, Savvina
    Guenat, Olivier T.
    Roesslein, Matthias
    Stucki, Janick D.
    Hirn, Stephanie
    Petri-Fink, Alke
    Rothen-Rutishauser, Barbara
    [J]. EUROPEAN JOURNAL OF NANOMEDICINE, 2015, 7 (03) : 169 - 179
12345